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Introduction: This study aimed to evaluate the long-term efficacy of 
multimodality therapy for patients with type B3 thymoma.
Methods: A total of 188 consecutive patients with type B3 were 
treated in our hospital from January 2001 to December 2010. One 
hundred seventy-seven patients who had been treated with curative 
intent were retrospectively analyzed. According to World Health 
Organization Classification, all patients were pathologically con-
firmed as type B3. Distribution of Masaoka stages I, II, III, and IV 
was 35 (19.8%), 20(11.3%), 78 (44.1%), and 44 (24.8%), respec-
tively. Myasthenia gravis coexisted in 34% of patients.
Results: After a mean follow-up of 49 months (7–135 months), 
the 10-year overall survival (OS) rates were 65% (89%, 86%, 61%, 
and 42% in stage I, II, III, and IV, respectively). One hundred five 
patients patients (102 patients with R0 resection and 3 with com-
plete response after radiotherapy) were analyzed for freedom from 
recurrence (FFR). The 5- and 10-year FFR rates were 91% and 73% 
(100%, 94%, 84%, 71% and 100%, 94%, 56%, N/A  in stages I, II, 
III, and IV, respectively. We have no data of stage IV.) TTP was cal-
culated on 72 patients including 57 patients with R+ resection and 15 
with partial response or stable disease after radiotherapy. The 5-year 
time-to-progression (TTP) rates were 33% (41%, 24% in stage III 
and IV, respectively). Multivariate analysis showed that prognostic 
factors for OS were the Masaoka stage and adjuvant radiation for 
patients with stage III and IV. The Masaoka stage and resection mar-
gin after surgery had significant effects on FFR and TTP.
Conclusion: The type B3 thymoma often presented with the later 
stages at the diagnosis. The Masaoka stage was closely associated 
with OS, FFR, and TTP. Resection margin after surgery was related 
to TTP. Adjuvant radiotherapy may be beneficial to stage III and IV 
patients in this clinical setting.
Key Words: Thymoma, Type B3, Postoperative, Radiotherapy, 
Thymectomy.
(J Thorac Oncol. 2013;8: 1329-1334)
Thymomas are unusual, low-grade malignant tumors of the thymic epithelium and the most common tumors of the 
anterior mediastinum with a low incidence of 2.5 to 3.2 per 
1,000,000 persons.1,2 The World Health Organization (WHO) 
classification3,4 is a systematic histologic classification and 
has been proved to be useful in distinguishing different clini-
cal characteristics of patients of a particular subtype from oth-
ers and has independent prognostic value. The proportion of 
B3 types reported went from 6% to 34%, and has been shown 
to be the worst prognosis (average 63 ± 19% of 10-year sur-
vival), compared with other subtype thymoma.This is because 
type B3 has shown more malignant behavior in terms of post-
operative survival, tumor recurrence, and local invasiveness.5,6 
It has been reported that patients with type B3 have the risk 
of invasiveness ranging from less than 40% to almost 90%.6,7 
The propensity of invasion to neighboring tissues, as reflected 
by the Masaoka clinicopathologic staging system, negatively 
affects prognosis of patients with type B3.8
There are no consensus guidelines for the treatment of 
type B3 thymoma. Although radical surgical resection remains 
the primary approach for the patients, the efficacy of adjuvant 
or neoadjuvant therapies is still controversial because of the 
lack of the confirmation of randomized trials. This retrospec-
tive study is the first to evaluate the long-term efficacy of mul-
timodality therapy for patients with a large cohorts of type B3 
thymoma patients.
PATIENTS AND METHODS
Patient’s Characteristics
From January 2001 to December 2010, 188 consecu-
tive patients with type B3 thymoma were treated in Shanghai 
Chest Hospital of Jiaotong University, China. One patient 
died of myasthenia gravis (MG) half a month after surgery, 10 
patients were lost at follow-up after the surgery. All patients 
had been pathologically confirmed as type B3 thymoma 
(WHO histologic classification) by surgery or needle biopsy, 
and most patients were treated by a combination of surgery 
and neoadjuvant or adjuvant therapy. Data from 177 patients 
were reviewed retrospectively.
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Treatment
Surgery
One hundred fifty-nine of 177 patients with stage I–IVa 
had undergone radical thymectomy, defined as the resection 
of the entire thymus and mediastinal fat tissue between both 
phrenic nerves. Surgical access through the median sternot-
omy was completed in 92 patients, thoracotomy in 53 patients, 
and video-assisted thoracoscopy in 14 patients. Biopsy or deb-
ulking was performed in 18 of 177 patients with stage III (3), 
IVa (2), and IVb (13). Thymoma was staged according to the 
Masaoka system.
External radiotherapy
There are neither consensus statements nor random-
ized trial data for analysis regarding the use of adjuvant 
radiation therapy, so the external beam radiotherapy (EBRT) 
was offered to the patients either with advanced stage, who 
received non-extirpative surgery or were recommended 
by surgeon. One hundred twenty-six of 177 patients (71%) 
received adjuvant EBRT (113 patients), neoadjuvant EBRT 
(5 patients) for resectable patients, or palliative EBRT (8 
patients) for nonsurgery patients. The EBRT techniques are 
described as the following: based on a preoperative computed 
tomography (CT) scan and surgical clips, the entire tumor bed 
and part of the involved adjacent organ with at least a 1.5-cm 
margin, when there was parenchymal involvement or as delin-
eated by surgical clips, were included in the radiation field. 
Treatment was delivered with 6 MV photons using multifield 
techniques (anteroposterior/posteroanterior, with 1–2 lateral 
fields) depending on dose coverage and the volume of organ 
at risk. A three-dimensional dose calculation was done during 
the treatment planning. The median doses was 49 Gy (range, 
36–66Gy), Additional 6 to 10 Gy was given to the tumor as a 
boost if R2 had been defined for the resectable patients.
Chemotherapy
 There is scant information about chemotherapy in type 
B3 thymoma. We did not develop a systematic chemother-
apy procedure. Chemotherapy were offered for some of the 
patients in advaced stage and who received palliative resec-
tion. Neoadjuvant chemotherapy was used in six patients (3%) 
who received two cycles of chemotherapy, another 29 patients 
(16%) received four cycles of adjuvant chemotherapy. The 
chemotherapy drugs involved were infosfamide, cyclophos-
phamide, cisplatinum, docetaxol fluorouracil, among others.
Follow-Up and Statistical Analysis
Patients were followed up according to protocol every 
3 months after the completion of treatment in the initial 2 
years, then every 6 months thereafter. Follow-up examina-
tions included complete history, physical examinations, com-
plete blood count, serum chemistry, ultrasound of liver, CT 
of the chest and abdomen or earlier, if recurrence was sus-
pected. The definition of recurrence was based on the stan-
dard of the International Thymic Malignancy Interest Group.9 
The duration of overall survival (OS) was calculated from the 
date of operation until death or the date of the last follow-up. 
Freedom from recurrence (FFR) was measured from the date 
of operation until the date of recurrence for patients who had 
no evidence of disease (i.e., an R0 resection or radiographic 
complete response) after a curative-intent treatment). Time to 
progress (TTP) was measured for patients in whom all disease 
was not eradicated (i.e., R1 or R2 resection, radiographic sta-
ble disease [SD], or partial response [PR]). The Kaplan–Meier 
method was used to estimate the OS, FFR, and TTP for the 
entire cohort and to perform univariate analysis for the assess-
ment of prognostic factors. The comparisons were tested using 
the log-rank test. Multivariate analysis was performed using 
the Cox regression model. Statistical analysis was performed 
using SPSS software version 12.0 (SPSS, Chicago, IL).
RESULTS
Treatment Outcome
Patients’ characteristics are detailed in Table 1. The 
median follow-up for all patients was 46 months (range, 15–
135 months). The median survival time was 49 months (range, 
7–135 months) for the entire group of patients. Of the 177 
patients, 102 underwent an R0 resection, 57 underwent R1 or 
R2 resection, 18 received biopsy or debulking, of which three 
TABLE 1.  Patient Characteristics
Variable Thymoma
Age
 Median 51 (17–83)
Sex
 Male 93 (52.5%)
 Female 84 (47.5%)
Masaoka stage
 I 35 (19.8%)
 II 20 (11.3%)
 III 78 (44.1%)
 IVa 31 (17.5%)
 IVb 13 (7.3%)
Myasthenia gravis
 Yes 54 (30.5%)
 No 123 (69.5%)
Tumor size
 ≤6 69 (39%)
 >6 108 (61%)
Residual disease
 R0 102 (57.6%)
 R1 32 (18.1%)
 R2 25 (14.1%)
 No surgery 18 (10.2%)
EBRT
 Yes 126 (71.2%)
 No 51 (28.8%)
Chemotherapy
 Yes 35 (19.8%)
 No 142 (80.2%)
EBRT, external beam radiotherapy; R0, no residual tumor; R1, microscopic residual 
tumor, R2, macroscopic residual tumor.
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patients achieved CR after curative radiotherapy. At the time 
of the analysis, 39 patients (22%) had disease recurrence and 
19 patients (12%) were deceased. The 5- and 10-year OS rates 
were 84%, 65% (100%, 89%, 86%, 60% and 89%, 86%, 61%, 
42% in stage I, II, III, and IV, respectively). One hundred five 
patients (102 patients with R0 resection and 3 patients with 
CR after radiotherapy) were analyzed for FFR. The 5-, 10-year 
FFR rates for the patients after R0 resection were 91% and 
73% (100%, 94%, 84%, 71% and 100%, 94%, 56%, N/S) in 
stage I, II, III and IV, respectively). TTP was calculated on 
72 patients including 57 patients with R+ resection and 15 
patients with PR or SD after radiotherapy. The 5-year TTP 
rates for the patients who had disease after treatment (i.e., R1, 
R2 resection; radiographic SD or PR after treatment) were 
33% (41% for R1, 24% for R2), respectively (Fig. 1).
Site of Recurrences
Recurrences developed in 39 patients (22%). Eight of 
39 patients had tumor bed recurrence, and pleural relapse was 
the most common site (35 of 39 patients). For 105 patients 
with either R0 resection or CR after radiotherapy, 14 of 
them had developed recurrence and 12 had pleural relapse. 
Thirteen patients (7%) had distant metastasis. The sites of 
distant metastasis were lung (3%), lymph nodes (2%), brain 
(1%), liver (2%), and bone (2%), respectively. There were four 
patients who developed both local and distant metastasis.
Prognostic Factors for OS, TTP, and FFR
All 177 patients treated with curative intent were ana-
lyzed for the prognostic factors of OS. One hundred five of 
them who were successfully treated patients (R0/CR) were 
used for the analysis of FFR, and 57 patients who were unsuc-
cessfully treated patients (R1, 2/PR, SD) were used for the 
analysis of TTP. The impact of age, sex, MG, tumor size, 
Masaoka stage, resection margin, surgery approach, and 
adjuvant radiation on OS, FFR, and TTP were studied in both 
uni- and multivariate analyses (Table 2). In the univariate anal-
ysis, the Masaoka stage was significantly associated with OS, 
FFR, and TTP (p < 0.05). Tumor size and adjuvant radiation 
for either all of patients or the patients with stages III to IV 
were the predictors of OS (p < 0.05). Chemotherapy was sig-
nificantly associated with TTP (p < 0.05). Multivariate analy-
sis revealed that the Masaoka stage and adjuvant radiation for 
patients with stage III to IV were independent prognostic fac-
tors for OS (p < 0.05) (Fig. 2). The positive resection margin 
negatively impacted on TTP (p = 0.03).
DISCUSSION
The prognostic value and clinical applicability of WHO 
classification systems have been confirmed in two other meta-
analysis studies.5,10 In this study, however, we are the first to 
analyze a large cohort of primary thymomas with particular 
emphasis on patients with type B3. One hundred seventy-
seven patients were retrospectively reviewed and were studied 
to elucidate and specify the factors predicting prognosis of 
thymoma after multimodal treatment.
Factors involving the prognosis of thymoma remain under 
discussion because of its rarity and indolent natural history. It 
is generally accepted that surgery is the mainstay treatment, 
and clear resection is one of the most independent prognostic 
factors for thymoma.11 In our series, 90% patients underwent 
extended thymectomy through different surgical accesses but 
with curative resection, the resectability had not negatively 
been impacted by the choice of surgical accesses and had not 
been associated with the prognosis of patients. However, the 
proportion of the complete resection could be significantly 
lower in patients affected by type B3 than in patients affected 
by other types reported, because type B3 closely correlated 
with the percentage of the invasive tumors, so that incomplete 
resection affected the prognostic value of type B3 histology.6,12 
FIGURE 1.  Kaplan–Meier curves for 10-year overall survival (A), freedom from recurrence (B), and time to progression (C) 
according to Masaoka stage for the entire group.
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Our data confirmed that 122 of 177 patients (69%) had invasive 
disease and all patients with incomplete resection had stage III 
and IV and had micro- or macroscopic invasion into surround-
ing structures such as the pleura, pericardium, and great ves-
sels before surgery. Incomplete resection had a significantly 
negative impact on TTP of type B3 in both uni- and multivari-
ate analyses in our study.
Large tumors (>8 cm in diameter) have been reported 
as a worse prognosis because they intuitively correlated 
with degree of invasion.13,14 Our data showed that 106 of 177 
FIGURE 2.  Kaplan–Meier curves for overall survival according to Masaoka stage (A) for the surgical group and adjuvant radio-
therapy according to Masaoka stage III and IV (B) for the resectable group (external beam radiotherapy).
TABLE 2.  Uni- and Multivariate Analyses for OS, FFR, and TTP
Variables
OSa FFR Survivala TTP Survivala
Univariate 
Analysis
Multivariate 
Analysis
Univariate 
Analysis
Multivariate 
Analysis
Univariate 
Analysis
Multivariate 
Analysis
Sex
(M vs. F) 0.41 0.99 0.88 0.77 0.37 0.76
Age, yr (≤60 vs. >60) 0.85 0.78 0.42 0.98 0.80 0.92
Myasthenia gravis
(yes vs. no) 0.06 0.84 0.36 0.27 0.31 0.12
Tumor size
(≤6 cm vs. >6 cm) 0.01 0.08 0.26 0.91 0.43 0.22
Masaoka’s stage
(I–II vs. III vs. IV) 0.00 0.04 0.00 0.02 0.01 0.05
Rection margin (R0 vs. R+) 0.00 0.81 NA NA 0.00 0.01
Surgery access (median sternotomy  
vs. lateral incision vs. VATS)
0.99 0.50 0.33 0.67 0.17 0.17
Radiotherapy (yes vs. no) 0.04 0.08 0.67 0.65 0.00 0.38
RT for I + II (yes vs. no) 0.40 NA 0.62 NA NA NA
RT for III + IV (yes vs. no) 0.00 NA 0.31 NA 0.00 NA
Chemotherapy (yes vs. no) 0.08 0.34 0.76 0.89 0.03 0.31
aData are expressed as p value.
EBRT, external beam radiotherapy; FFR, freedom from recurrence; NA, not applicable; OS, overall survival; TTP, time to progression; R0, no residual tumor; R1, microscopic 
residual tumor, R2, macroscopic residual tumor.
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patients (60%) had tumor size greater than 6 cm in diameter 
and 85 of them (80%) had staged as III or IV, indicating that 
there was a correlation with tumor invasion (data not shown). 
Tumor size was a worse predictor of the OS in the univariate 
analysis in the current study, but failed to correlate with OS, 
FFR, and TTP of type B3 thymoma patients in multivariate 
analysis; this could be explained by the fact that tumor extent, 
as proposed in the Masaoka staging system, is more relevant 
than tumor dimension.15 However, the Masaoka stage is very 
difficult to be assigned before resection because invasion is 
difficult to differentiate from simple abutment on the CT scan. 
Tumor size may be useful for the decision making of therapeu-
tic choice before resection because neoadjuvant therapy might 
have better survival advantages than that adjuvant therapy for 
late advanced thymomas.16
It remains controversial whether MG is one of the prog-
nostic factors for thymoma. Some studies have shown that the 
association with MG was one of the risk factors for OS in 
multivariate analysis,17 but other recent studies reported that 
MG does not influence the survival or is even associated with 
better prognosis because symptoms of MG might lead to early 
diagnosis.18–20 The incidence of MG in thymoma is relatively 
low in A and C subtypes compared with B subtype, and varies 
from 25% to 65% for type B3 in most reports.10,21 In our study, 
30.5% of type B3 patients had accompanied with MG. Both 
uni- and multivariate analyses have not shown that MG was 
associated with 10-year OS, FFR, and TTP. Therefore, it is 
necessary to further clarify whether MG would influence the 
prognosis of type B3 thymoma.
In past literature,7 the Masaoka staging system has been 
shown to be an independent prognostic factor in all subtype 
thymomas. Our present study demonstrated that the Masaoka 
stage was an independent prognostic factor for type B3 thy-
moma in both uni- and multivariate analyses. There were 
significant differences among stage I/II versus III versus IVa 
in terms of OS and FFR (p = 0.04, p = 0.01, respectively). 
Type B3 is of more aggressive nature than other subtypes, 
around 60% to 90% of patients were staged as III or IV at the 
first diagnosis as reported.22 One hundred twenty-two of 177 
patients (68.9%) in our study had invasive disease and were 
at Masaoka III or IV. B3 thymomas are more aggressive than 
other thymomas,23 and 5-year survival rate was around 50% 
(stage III–IV).24 Therefore, multimodality therapies including 
neoadjuvant chemotherapy, surgery, adjuvant chemotherapy, 
and radiotherapy warrant further study for this particular pop-
ulation of patients.
Evaluation of the role of radiation therapy in the man-
agement of malignant thymoma, or patients with incom-
plete resection, and as such, adjuvant radiotherapy, could 
maximize local control, even improve survival.24,25 Adjuvant 
radiotherapy is not usually recommended after a totally 
resected stage I thymoma. Although the incidence of intra-
thoracic recurrence for patients with stage II and III has 
been about 28% to 40% after surgery alone,24,26 there was 
some controversy about the positive effects of the addition 
of postoperative radiotherapy, especially for patients with 
stage II and III after complete resection.27,28 In our study, 
adjuvant radiotherapy had no impact on the OS, FFR, and 
TTP in multivariate analyses. Although the patients were 
stratified based on Masaoka stage, adjuvant radiotherapy 
improved the OS for stage III to IV patients in multivariate 
analyses.
Postoperative mediastinal irradiation was usually used to 
prevent local recurrence, but it was unable to prevent regional 
recurrence like pleural dissemination. As we observed in our 
study, 35 of 43 locally recurrent patients presented with pleural 
site, and this may compromise the efficacy of adjuvant radio-
therapy for the local control. Therefore, some authors have 
advocated the adoption of prophylactic radiotherapy to the 
entire hemithorax against pleural dissemination and achieved 
a better 5-year relapse-free rate when compared with those 
obtained by mediastinal irradiation alone.29,30 Because most 
treatment recommendations have been based on retrospective 
data, the role of adjuvant radiotherapy has to be further clari-
fied in more randomized studies.
To our knowledge, we report the largest series of type 
B3 thymoma managed with radical surgery and combined 
with or without adjuvant therapy. However, we consider our 
results far from conclusive, and several important issues need 
to be addressed. First, the patients’ treatment was not arranged 
according to a prospective institutional treatment protocol, it 
was certainly a substantial pitfall in our study. In addition, our 
study was a retrospective analysis and most of patients received 
adjuvant therapy, hence the number of patients required for 
a set level of statistical power may not have been enough to 
determine the role of adjuvant therapy. Finally, although the 
mathematical model of statistical analysis package could take 
the short follow-up time of some patients into consideration, 
the conclusions may still be biased and have to be interpreted 
with caution. All these issues need to be further addressed in 
future prospective clinical trials.
In conclusion, we retrospectively reviewed the out-
come of type B3 thymoma with the largest cohorts of patients 
as reported. Our data showed that type B3 was in a more 
advanced stage at the first diagnosis. Surgery remains the 
mainstay treatment and the residual status after surgery was 
an independent prognostic factor, in addition to the Masaoka 
stages and adjuvant radiotherapy for stage III to IV patients. 
Given the nature of retrospective analysis, our results should 
be confirmed by further prospective studies.
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